Company news

Vanda Pharmaceuticals Inc. news in 2025

Vanda Pharmaceuticals Inc.'s news releases, calls and decks from 2025, newest first.

View company

Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness

December 29, 2025

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

December 14, 2025

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

December 10, 2025

FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness

December 3, 2025

Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness

November 27, 2025

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting

November 16, 2025

Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference

November 4, 2025

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

October 28, 2025

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

October 21, 2025

Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

October 8, 2025

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

September 30, 2025

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

September 24, 2025

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

August 27, 2025

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

August 27, 2025

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

August 20, 2025

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

August 17, 2025

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

July 30, 2025

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

July 22, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

June 9, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

May 26, 2025

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

May 15, 2025

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

May 6, 2025

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

May 4, 2025

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

May 1, 2025

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

April 23, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

April 6, 2025

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

March 30, 2025

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

February 23, 2025

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

February 12, 2025

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

February 4, 2025

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

February 2, 2025

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

January 26, 2025

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

January 7, 2025

Calls in 2025

Decks in 2025